Deinove: industrial production of carotenoids begins, animal testing results due

By Jane Byrne

- Last updated on GMT

© GettyImages/EtiAmmos
© GettyImages/EtiAmmos

Related tags Animal nutrition Antioxidant Metabolism

French biotech company, Deinove, says the results of extensive in vivo efficacy and bioavailability trials on its bacteria derived carotenoid compounds in poultry and fish diets will be released next month.

In animal feed applications, the ideas is that those compounds would be used mainly for pigmentation of skin and yolks but they do have nutritional value as well in terms of antioxidant functionality, the Montpellier headquartered company told us earlier this year.

The fish and poultry trials were run to replicate earlier findings but in a larger cohort of animals. They form part of a strategic project Deinove collaborates in with French agribusiness group, Avril, and through an initiative in the US with Flint Hills Resources.  

Yesterday [20 December] also saw Deinove, which was set up to discover, develop, and produce high-value compounds from rare bacteria, notably from the Deinococcus genus, announce the launch of the industrial production of its first carotenoid.  

However, CEO of Deinove, Emmanuel Petiot, told us this commercial phase is only targeting food supplement and cosmetic applications, not animal nutrition; the scale up involves the use of a toll manufacturer – SAS Pivert.

The company said it has developed an optimized process in terms of performance and robustness on a 20-liter scale.

Chinese patent

Earlier this year, Deinove reported that its first patent focusing on the use of the bacteria, Deinococcus, for animal nutrition had been issued in China.

Petiot said then that the patent demonstrated the progress it has made in the animal nutrition sector in the past three years.

“China is the world's largest producer of livestock, it is therefore essential that we can eventually market our innovations there with all the necessary protections. However, this patent is intended to be issued in all other major territories,” ​he added.

Deinove has nearly 160 international patent applications. 

The company, which has been listed on the Alternext since April 2010, cites two key assets in terms of its development plan: its strain bank with 6,000 rare bacteria that have not yet been exploited and its genetic, metabolic and fermentation engineering platform that enables it to customize these natural micro-factories. 

Related news

Show more

Related products

show more

A pioneer and leader in microbial fermentation

A pioneer and leader in microbial fermentation

Content provided by Lallemand Animal Nutrition | 05-Dec-2023 | Business Advice

For over 100 years we've been producing yeast and bacteria for a variety of markets, Lallemand has perfected the art of fermentation. As primary microorganism...

YeaMOS T—Special Yeast Cell Wall for Mycotoxin Bin

YeaMOS T—Special Yeast Cell Wall for Mycotoxin Bin

Content provided by Angel Yeast - animal nutrition | 11-Oct-2023 | Research Study

YeaMOS T, which has been strengthened the advantages of adsorption sites in the yeast cell wall and possesses excellent adsorption effect in the toxins.

Animal AgTech San Francisco, March 18-19, 2024

Animal AgTech San Francisco, March 18-19, 2024

Content provided by Animal AgTech Innovation Summit | 15-Aug-2023 | White Paper

Animal AgTech is the go-to meeting place for the meat and dairy supply chain to accelerate action for animal health and environmental stewardship.

Related suppliers

Follow us

Products

View more

Webinars